Bart C. Kuenen

1.6k total citations
31 papers, 1.2k citations indexed

About

Bart C. Kuenen is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Bart C. Kuenen has authored 31 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Bart C. Kuenen's work include Cancer Treatment and Pharmacology (8 papers), Angiogenesis and VEGF in Cancer (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Bart C. Kuenen is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Angiogenesis and VEGF in Cancer (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Bart C. Kuenen collaborates with scholars based in Netherlands, United States and Germany. Bart C. Kuenen's co-authors include Herbert M. Pinedo, Giuseppe Giaccone, Marcel Levi, Klaas Hoekman, Victor W.M. van Hinsbergh, A.K. Kakkar, Joost C.M. Meijers, Rita Ruijter, K. Hoekman and Marja Visser and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Bart C. Kuenen

30 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bart C. Kuenen Netherlands	17	519	511	264	176	159	31	1.2k
Iuliana Shapira United States	20	787 1.5×	244 0.5×	247 0.9×	442 2.5×	133 0.8×	53	1.6k
Som D. Mukherjee Canada	25	968 1.9×	560 1.1×	499 1.9×	414 2.4×	110 0.7×	85	2.0k
Terry A. Vik United States	24	439 0.8×	795 1.6×	138 0.5×	126 0.7×	379 2.4×	79	2.1k
Christine Walsh United States	30	874 1.7×	845 1.7×	349 1.3×	391 2.2×	69 0.4×	93	2.6k
Michael Koenigsmann Germany	20	436 0.8×	227 0.4×	290 1.1×	94 0.5×	405 2.5×	63	1.5k
Albert Font Spain	22	720 1.4×	498 1.0×	874 3.3×	381 2.2×	87 0.5×	75	1.7k
Thorsten Fuereder Austria	21	804 1.5×	448 0.9×	387 1.5×	180 1.0×	42 0.3×	92	1.5k
Francisco Ayala Spain	24	774 1.5×	492 1.0×	240 0.9×	352 2.0×	261 1.6×	105	2.0k
Gianluca Spitaleri Italy	26	1.1k 2.2×	504 1.0×	985 3.7×	327 1.9×	46 0.3×	83	2.1k
Carmen Guillén‐Ponce Spain	24	1.0k 1.9×	384 0.8×	434 1.6×	463 2.6×	36 0.2×	133	1.9k

Countries citing papers authored by Bart C. Kuenen

Since Specialization

Citations

This map shows the geographic impact of Bart C. Kuenen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart C. Kuenen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart C. Kuenen more than expected).

Fields of papers citing papers by Bart C. Kuenen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart C. Kuenen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart C. Kuenen. The network helps show where Bart C. Kuenen may publish in the future.

Co-authorship network of co-authors of Bart C. Kuenen

This figure shows the co-authorship network connecting the top 25 collaborators of Bart C. Kuenen. A scholar is included among the top collaborators of Bart C. Kuenen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart C. Kuenen. Bart C. Kuenen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Osinga, Thamara E., Sjoukje F. Oosting, Peter van der Meer, et al.. (2022). Immune checkpoint inhibitor–associated myocarditis. Netherlands Heart Journal. 30(6). 295–301. 13 indexed citations

Kaye, Stan B., Steinar Aamdal, Richard D. Jones, et al.. (2012). Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. British Journal of Cancer. 106(11). 1728–1734. 29 indexed citations

Kuenen, Bart C., Petronella O. Witteveen, Rita Ruijter, et al.. (2010). A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 16(6). 1915–1923. 66 indexed citations

Hanauske, A.-R., Michael Lahn, Luna Musib, et al.. (2009). Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. Annals of Oncology. 20(9). 1565–1575. 21 indexed citations

Giovannetti, Elisa, Richard J. Honeywell, Axel R. Hanauske, et al.. (2009). Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC). Current Drug Targets. 11(1). 12–28. 13 indexed citations

Cruijsen, Hester van, Klaas Hoekman, Anita G.M. Stam, et al.. (2007). Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor. SHILAP Revista de lepidopterología. 2007. 1–9. 24 indexed citations

Hanauske, Axel-Rainer, Luna Musib, K. Weigang-Köhler, et al.. (2007). Comparison of enzastaurin pharmacokinetics and safety in the once daily (QD) and twice daily (BID) dose regimens: A phase I study. Journal of Clinical Oncology. 25(18_suppl). 14021–14021. 1 indexed citations

Bröker, Linda E., Stephan A. Veltkamp, Elisabeth I. Heath, et al.. (2007). A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183. Clinical Cancer Research. 13(13). 3906–3912. 21 indexed citations

Kuenen, Bart C., Els O. Witteveen, Rita Ruijter, et al.. (2006). A phase I study of IMC-11F8, a fully human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors. Interim results. Journal of Clinical Oncology. 24(18_suppl). 3024–3024. 7 indexed citations

10.

Hanauske, A.-R., Bart C. Kuenen, D. Thornton, et al.. (2006). Pharmacokinetic interaction and safety of enzastaurin and pemetrexed in patients with advanced or metastatic cancer. Journal of Clinical Oncology. 24(18_suppl). 2047–2047. 9 indexed citations

11.

Bröker, Linda E., Filip De Vos, Cees J. van Groeningen, et al.. (2006). Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity. Clinical Cancer Research. 12(6). 1760–1767. 19 indexed citations

12.

Hensbergen, Yvette van, Bart C. Kuenen, P. J. van Diest, et al.. (2004). A patient with a VEGF and endostatin producing gastrointestinal autonomic nerve tumour. Journal of Clinical Pathology. 57(5). 536–538. 3 indexed citations

13.

Kuenen, Bart C., Josep Tabernero, José Baselga, et al.. (2003). Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.. PubMed. 9(5). 1648–55. 103 indexed citations

14.

Kuenen, Bart C., Marcel Levi, Joost C.M. Meijers, et al.. (2003). Potential Role of Platelets in Endothelial Damage Observed During Treatment With Cisplatin, Gemcitabine, and the Angiogenesis Inhibitor SU5416. Journal of Clinical Oncology. 21(11). 2192–2198. 91 indexed citations

15.

Kuenen, Bart C.. (2003). Analysis of Prothrombotic Mechanisms and Endothelial Perturbation during Treatment with Angiogenesis Inhibitors. Pathophysiology of Haemostasis and Thrombosis. 33(1). 13–14. 22 indexed citations

16.

Kuenen, Bart C., Marcel Levi, Joost C.M. Meijers, et al.. (2002). Analysis of Coagulation Cascade and Endothelial Cell Activation During Inhibition of Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Pathway in Cancer Patients. Arteriosclerosis Thrombosis and Vascular Biology. 22(9). 1500–1505. 123 indexed citations

17.

Ong, L.M.L., Marja Visser, Frits B. Lammes, et al.. (2000). Effect of Providing Cancer Patients With the Audiotaped Initial Consultation on Satisfaction, Recall, and Quality of Life: A Randomized, Double-Blind Study. Journal of Clinical Oncology. 18(16). 3052–3060. 109 indexed citations

18.

Kuenen, Bart C., et al.. (1996). Non-islet-cell tumour induced hypoglycaemia: a case report and review of literature. The Netherlands Journal of Medicine. 48(5). 175–179. 8 indexed citations

19.

Rotteveel, Francien T.M., et al.. (1990). Relative increase of inflammatory CD4+ T cells in the cerebrospinal fluid of multiple sclerosis patients and control individuals. Clinical & Experimental Immunology. 79(1). 15–20. 9 indexed citations

20.

Rotteveel, Francien T.M., René A. W. van Lier, Bart C. Kuenen, et al.. (1988). Clonal analysis of functionally distinct human CD4+ T cell subsets.. The Journal of Experimental Medicine. 168(5). 1659–1673. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact